Demand drives interest in oncology drug makers

While venture capital funds chase a shrinking number of deals in China, the pharmaceutical sector remains a bright light.

Carol Huang

January 08, 2019

Apollomics, a Sino-US oncology drug company, has raised $100 million in Series B funding from a group of Chinese investors.

Registered users get 2 free articles in 30 days.

Subscribers have full unlimited access to FinanceAsia.

Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.

Questions?
See here for more information on licences and prices, or contact [email protected].